Juan Carlos Leza
The work is published in a well-known journal within the field of cell biology—one that employs external peer review, is ranked in the top quartile (Q1) for its area, and so on. The presentation and justification of the topic, the description of the biological samples (brain tissue from 100 individuals who died with a diagnosis of major depressive disorder, PTSD, or as controls), and the application of the techniques are all well documented. The techniques themselves are established and appropriate for the study's objectives. The authors also clearly outline the study's limitations (such as issues related to sample enrichment) and disclose any potential conflicts of interest.
The authors—members of an international consortium that has been publishing research for over a decade—present a more sophisticated study than others previously released by the same group. They examine changes in specific brain nuclei that are crucial for regulating mood and stress—areas fundamental to understanding the pathophysiology (as well as the symptoms and treatment response) of major depressive disorder and PTSD.
This is not a pioneering study, in the sense that other research has already evaluated DNA methylation in the brain within the context of neuropsychiatric conditions. Changes in DNA methylation in the human brain indicate that the epigenome of those cells has been altered. While the genetic sequence itself remains unchanged, these modifications provide insight into the extent to which certain genes are activated or silenced.
Such changes can stem from a variety of factors—ranging from lifestyle and environmental influences to the natural passage of time and, of course, specific pathological processes. Determining their precise significance depends on where they occur, the cell type involved, and the direction of the change; however, further research beyond what is presented here is required to fully understand these implications.
The underlying principle has been understood for decades: neuropsychiatric disorders (among many others) result from an interplay between genes and the environment, which can lead a "vulnerable" individual to develop symptoms or manifest a clear clinical condition. In the case of depression... In the case of major depression or PTSD, the number of genes involved is much smaller than in other conditions, such as schizophrenia or autism spectrum disorders—yet, such genes do exist.
Through a process of interaction, certain vulnerable periods in life (childhood, adolescence, and even adulthood) can involve factors that modify—either by enhancing or silencing—the function of genes responsible for regulating synapses, neurotransmitters, the activity of specific neurons, and more. These processes lead to gene methylation. Such factors may include stress, abuse, exposure to toxins, persistently high levels of glucocorticoids, infections, or immunological challenges, among others.
Clearly, one of the primary strengths of this research is that it provides access to actual brain tissue—something impossible to achieve in a living patient (as brain biopsies cannot, obviously, be performed). The closest we can get is by analyzing, for example, cerebrospinal fluid—a procedure that carries risks and requires ethical justification—or by examining samples such as blood, urine, or saliva. Significant effort has been invested in identifying biomarkers within these peripheral samples that could serve for prognosis, predicting therapeutic response, or diagnosing brain disorders. While we will likely get closer to this goal in the future, we cannot currently guarantee that the mediators found in an individual’s plasma or blood are the same—or present at the same concentrations—as those found within the brain, or within a specific brain region or circuit.
It is true that neuroimaging techniques allow us to observe the quantity and location of markers of brain activity in living individuals; however, we are still far from being able to apply these biomarkers in a clinical setting.
In the meantime, studies using post-mortem tissue offer the advantage of examining the very tissue in which the disease resides—though many other variables must be taken into account, such as the time elapsed since death, the stability of the tissue prior to freezing or fixation, and various other factors. ...many factors, such as the ultimate cause of death, the presence of drugs or toxic substances at that time, etc.
In any case, the discovery—as reported by these authors—of changes in gene methylation in patients with depression and PTSD is definitely an important step toward personalized medicine. The study accounts for significant factors, such as age and sex. There is still a long way to go, but the goal is to be able to use these "markers" to clearly diagnose a condition or predict its response to a specific treatment—and, of course, to attempt to devise pharmacological (or non-pharmacological) strategies to "restore to normal" those processes that modulate gene activity.
[Regarding potential limitations] In general, I would like to emphasize that correlation does not equal causation: a change—in this case, in the methylation of a gene—does not necessarily explain the phenotype (as is the case with the polygenic conditions discussed in the article). Furthermore, one must also consider post-mortem effects; these studies utilize tissue from deceased donors, involving variables such as the post-mortem interval, cause of death, and medication use. And, of course, we are still waiting to see whether these findings—much like others already published along the same lines—can be translated into clinical practice and real-world application."